A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin’s Lymphoma Who Have Received Prior Treatment

Inclusion Criteria:

Any stage, histologically confirmed CD20-positive primary or transformed diffuse large B cell lymphoma (DLBCL)or grade 3 follicular lymphoma (FL)
Ineligible for or have previously received an autologous stem cell transplant (ASCT)
Relapsed following receipt of the last dose of systemic chemotherapy or ASCT
At least one prior chemotherapy regimen. Prior chemotherapy regimen must have contained anthracycline (unless contraindicated)
If the subject is female, she must be non-pregnant and non-lactating at the Baseline Visit. All sexually active males and females of childbearing potential must agree to use an adequate method of contraception throughout the study period
Eastern Cooperative Oncology Group (ECOG) performance status
Exclusion Criteria:

Use of any standard/experimental anti-lymphoma drug therapy within 21 days of the Baseline Visit
Use of systemic steroids within 5 days of the Baseline Visit (except for the purposes of pre-medication prior to study regimen treatment)
Prior allogeneic stem cell transplant (SCT)
The subject has been previously treated with YM155
The subject has known human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibody
The subject has received other investigational therapy or procedures within 21 days prior to the first study drug administration